Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Satsuma Pharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is assigned to HAGHIGHATIAN, MINA, who is the busiest examiner for the company with 1 pending action. This single pending action represents the current focus of the company's patent prosecution efforts.
The portfolio's current activity involves 1 distinct examiner and 1 distinct art unit. The 1 distinct art unit indicates that the company's current filings are concentrated within a specific technical division at the patent office. With only 1 pending office action, the company's immediate administrative burden is low. The presence of 1 distinct examiner means that the company's current success in this area is dependent on the review of one individual. This concentrated activity allows for a simple and direct response to the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18479335 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18479335 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE | HAGHIGHATIAN, MINA | 1616 | DP | Non-Final OA | — | Pending | Oct 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSatsuma Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mina Haghighatian has the most, with 1 of Satsuma Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
